Precision BioSciences Inc. is a biotechnology company that was founded in 2006 with the goal of improving gene editing technologies for use in a wide range of applications. The company is based in Durham, North Carolina, and has a team of scientists, researchers, and business professionals focused on advancing the field of genome editing.
The company's proprietary ARCUS genome editing platform is a next-generation gene editing tool that has the potential to significantly improve the efficiency, precision, and safety of genome editing. ARCUS uses a natural enzyme called the homing endonuclease to make precise, targeted cuts in DNA sequences, allowing for the insertion, deletion, or replacement of specific genes.
Precision BioSciences is focused on developing therapies for genetic diseases, with a particular focus on oncology, genetic disorders, and infectious diseases. The company is also actively pursuing partnerships and collaborations with other biotech companies and research institutions to explore the full potential of its ARCUS technology.
Precision BioSciences has several ongoing clinical trials, including a phase 1/2a trial for its allogeneic CAR T cell therapy for relapsed or refractory non-Hodgkin's lymphoma, and a phase 1 trial for its in vivo gene correction therapy for sickle cell disease.
In addition to its therapeutic applications, Precision BioSciences is also exploring the use of ARCUS for other applications, such as agricultural biotechnology and industrial bioprocessing. The company has partnered with several companies in these industries to explore the potential of its gene editing technology.
Precision BioSciences has raised over $300 million in funding to date from investors such as Fidelity Management & Research Company, ArrowMark Partners, Franklin Templeton, and Cormorant Asset Management. The company went public in 2019 and is traded on the NASDAQ stock exchange under the ticker symbol DTIL.